PA
VIVO

Parallel Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Parallel Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-40
Closed -$1.33K – 3556
2022
Q4 		$1.33K Sell
40
-65
-62% -$2.09K ﹤0.01% 2819
2022
Q3 		$3K Buy
105
+65
+163% +$2.1K ﹤0.01% 2559
2022
Q2 		$1K Hold
40
– – ﹤0.01% 2925
2022
Q1 		$1K Sell
40
-14
-26% -$333 ﹤0.01% 2906
2021
Q4 		$1K Buy
+54
New +$1.03K ﹤0.01% 3017
2019
Q2 		– Sell
-153
Closed -$3K – 2479
2019
Q1 		$3K Hold
153
– – ﹤0.01% 2034
2018
Q4 		$2K Hold
153
– – ﹤0.01% 1941
2018
Q3 		$2K Hold
153
– – ﹤0.01% 2077
2018
Q2 		$2K Hold
153
– – ﹤0.01% 1914
2018
Q1 		$2K Hold
153
– – ﹤0.01% 1913
2017
Q4 		$2K Hold
153
– – ﹤0.01% 1922
2017
Q3 		$2K Sell
153
-369
-71% -$5.27K ﹤0.01% 1919
2017
Q2 		$7K Sell
522
-237
-31% -$3.41K ﹤0.01% 1471
2017
Q1 		$11K Buy
759
+592
+354% +$8.28K ﹤0.01% 1204
2016
Q4 		$3K Buy
+167
New +$2.93K ﹤0.01% 1565

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Parallel Advisors's VIVO Position: Q1 2023 in Review

Parallel Advisors sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 40 shares — an estimated $1.33K sold.

Parallel Advisors first reported a position in VIVO in Q4 2016 and held it in 15 quarters. The position peaked at $11K in Q1 2017. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • Parallel Advisors reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • Parallel Advisors sold 40 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.33K.
  • Parallel Advisors first reported a position in Meridian Bioscience Inc in Q4 2016 and held it in 15 quarters.
  • Parallel Advisors's Meridian Bioscience Inc position peaked at $11K in Q1 2017.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Parallel Advisors's 13F filing for Q1 2023, filed 25 Apr 2023.